高级检索
    陈丽娟, 叶永青, 李殿明. 安罗替尼治疗晚期非小细胞肺癌的疗效及安全性评价[J]. 蚌埠医科大学学报, 2021, 46(5): 623-626. DOI: 10.13898/j.cnki.issn.1000-2200.2021.05.016
    引用本文: 陈丽娟, 叶永青, 李殿明. 安罗替尼治疗晚期非小细胞肺癌的疗效及安全性评价[J]. 蚌埠医科大学学报, 2021, 46(5): 623-626. DOI: 10.13898/j.cnki.issn.1000-2200.2021.05.016
    shu
    CHEN Li-juan, YE Yong-qing, LI Dian-ming. Evaluation of the efficacy and safety of amlotinib in the treatment of advanced non-small cell lung cancer[J]. Journal of Bengbu Medical University, 2021, 46(5): 623-626. DOI: 10.13898/j.cnki.issn.1000-2200.2021.05.016
    Citation: CHEN Li-juan, YE Yong-qing, LI Dian-ming. Evaluation of the efficacy and safety of amlotinib in the treatment of advanced non-small cell lung cancer[J]. Journal of Bengbu Medical University, 2021, 46(5): 623-626. DOI: 10.13898/j.cnki.issn.1000-2200.2021.05.016
    shu

    安罗替尼治疗晚期非小细胞肺癌的疗效及安全性评价

    Evaluation of the efficacy and safety of amlotinib in the treatment of advanced non-small cell lung cancer

      摘要
    • 摘要:
      目的探讨安罗替尼治疗晚期非小细胞肺癌（NSCLC）的疗效及安全性。
      方法回顾性分析应用安罗替尼治疗的50例晚期NSCLC病人资料，其中有45例病人接受安罗替尼三线治疗，5例病人接受四线治疗。分析评估安罗替尼的疗效及安全性。
      结果最终47例病人纳入研究，无完全缓解的病人，部分缓解2例（4.26%），病情稳定24例（51.06%），病情进展21例（44.68%）。客观缓解率及疾病控制率分别是4.26%和55.32%，中位总生存时间（mOS）及中位无进展生存时间（mPFS）分别是8.6个月（95%CI 5.853~11.347）和4.8个月（95%CI 2.904~6.696）；≥60岁病人mOS及mPFS分别为8.6个月（95%CI 5.853~11.347）、5.8个月（95%CI 4.283~7.317）。使用安罗替尼发生的不良反应基本可耐受，发生率较高的不良反应为厌食、咯血、肝功能异常、手足综合征、高血压。
      结论安罗替尼作为晚期NSCLC病人三线及以上治疗是可行的方案。

       

      Abstract:
      ObjectiveTo explore the efficacy and safety of anlotinib in the treatment of advanced non-small cell lung cancer(NSCLC).
      MethodsThe clinical data of 50 advanced NSCLC patients treated with anlotinib were retrospectively analyzed.Forty-five patients were treated with anrotinib of third-line drug, and 5 patients were treated with fourth-line drug.The efficacy and safety of anlotinib were analyzed.
      ResultsForty-seven patients were investigated, and the complete response in 0 case, partial response in 2 cases(4.26%), stable disease in 24 cases(51.06%) and disease progression in 21 cases(44.68%) were found.The objective response rate(ORR) and disease control rate(DCR) were 4.3% and 55.3%, respectively.The median overall survival(mOS) and median progression-free survival(mPFS) were 8.6 months(95%CI 5.853-11.347) and 4.8 months(95%CI 2.904-6.696), respectively.The mOS and mPFS in elderly patients(≥ 60 years old) were 8.6 months(95%CI 5.853-11.347) and 5.8 months(95%CI 4.283-7.317), respectively.The adverse reactions caused by the use of amlotinib were basically tolerable, and the high incidence rate of adverse reactions included anorexia, hemoptysis, abnormal liver function, hand-foot syndrome and hypertension.
      ConclusionsAnlotinib is a viable option for third-line and above in patients with advanced NSCLC

       

      • HTML全文
      • 参考文献(19)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回